The company agreed to potentially sell Synthes’ trauma unit to appease regulators. A ruling is expected by April 26 on the $21.3 billion takeover. Boards of both companies approved the acquisition.
Sign up for our FREE Orthopedic E-Weekly for more coverage like this sent to your inbox!
Related Articles on Orthopedic Devices:
Medtronic’s Biologics Business Down 20% in 3Q With Infuse Sales Dropping
DJO Global Finalizes, Expands Partnership With Lima
ArthroCare Revenues Down in 2011
Johnson & Johnson May Sell Synthes’ Orthopedic Trauma Unit to Appease Regulators
Johnson & Johnson recently made concessions to convince the European Union’s antitrust regulator that it’s acquisition of Swiss company Synthes is clear of any issues, according to a New York Times report.
